All In Biotech

Drug Trial Radar · NCT00121524

Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome

Effects of Epinephrine and I.V. Needle on CPR Outcome

Last checked: Nov 20, 2026Latest source record: May 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 904 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

904

Actual

Start

Jan 2003

Primary completion

May 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Petter Andreas SteenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Laerdal Medical; Ullevaal University Hospital; Health Region East, Norway; Norwegian Air Ambulance Foundation; University of Oslo
First posted
Jul 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.

Conditions

  • Cardiac Arrest

Interventions

  • EpinephrineDrug

    Epinephrine 1 mg is given iv. every 3 min during CPR

  • Intravenous needleDevice

    An intravenous needle in placed as soon as possible during CPR

  • AtropineDrug

    Atropine 3 mg iv in initial systole

  • AmiodaroneDrug

    amiodarone 300 mg iv after repeated failed defibrillation attempts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. survival to hospital discharge with neurologic outcomeTime frame: discharge from hospital

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ulleval University Hospital

    Oslo, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.